DNATRIX, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2005-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.dnatrix.com
DNX-2440 for Resectable Colorectal Liver Metastasis
Phase 1
Suspended
- Conditions
- Colorectal CancerSquamous Cell CarcinomaLiver Metastasis Colon CancerMelanomaSarcomaLiver MetastasesGastric CancerPeriampullary CancerRenal Cell CancerGastrointestinal Stromal Tumors
- Interventions
- Biological: DNX-2440
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- DNAtrix, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04714983
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, Florida, United States
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
Phase 2
Completed
- Conditions
- Brain CancerGlioblastomaNeoplasm by Histologic TypeNervous System DiseasesBrain NeoplasmGliosarcomaMalignant Brain TumorNeoplasm, NeuroepithelialGliomaNeuroectodermal Tumors
- Interventions
- Biological: DNX-2401Biological: pembrolizumab
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- DNAtrix, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT02798406
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
Phase 1
Completed
- Conditions
- Glioblastoma or Gliosarcoma
- Interventions
- Drug: Single intratumoral injection of DNX-2401
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- DNAtrix, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT02197169
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸The Ohio State University, Columbus, Ohio, United States
🇺🇸Baylor University: Charles A. Sammons Cancer Center, Dallas, Texas, United States
DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas
Phase 1
Completed
- Conditions
- Central Nervous System DiseasesBrain Cancer
- Interventions
- Procedure: Tumor Removal
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- DNAtrix, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT00805376
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States